![Darcy Mootz](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Darcy Mootz
Keine laufenden Positionen mehr
Profil
Darcy Mootz is currently Director at Alpha-9 Oncology, Inc. and President at Architect Therapeutics, Inc. Former roles include Senior Director-Corporate Development at Achaogen, Inc., Independent Director at Elevation Oncology, Inc. from 2024 to 2025, Head at Amunix Pharmaceuticals, Inc. from 2022 to 2023, and Chief Business Officer at Oric Pharmaceuticals, Inc. Education includes undergraduate studies at Duke University and a doctorate from Harvard University.
Aktive Positionen von Darcy Mootz
| Unternehmen | Position | Beginn |
|---|---|---|
Alpha-9 Oncology, Inc.
 Alpha-9 Oncology, Inc. BiotechnologyHealth Technology Engages in research clinical stage radiopharmaceutical and drug design for cancer treatment | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Darcy Mootz
| Unternehmen | Position | Ende |
|---|---|---|
| ELEN ONCO | Direktor/Vorstandsmitglied | 23.07.2025 |
Amunix Pharmaceuticals, Inc.
 Amunix Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops transformative T cell engagers (TCEs) and cytokine therapies for patients with cancer | Corporate Officer/Principal | 01.04.2023 |
| ORIC PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
| ACHAOGEN | Corporate Officer/Principal | - |
Ausbildung von Darcy Mootz
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
35
Beziehungen ersten Grades
7
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 7 |
|---|---|
Achaogen, Inc.
 Achaogen, Inc. Pharmaceuticals: MajorHealth Technology Operates as a a biopharmaceutical company, which engages in the research, development, and commercialization of antibacterial treatments for multi-drug resistant (MDR) gram-negative infections | Health Technology |
Duke University
 Duke University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Oric Pharmaceuticals, Inc.
 Oric Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops pharmaceutical products | Health Technology |
Amunix Pharmaceuticals, Inc.
Amunix Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops transformative T cell engagers (TCEs) and cytokine therapies for patients with cancer | Health Technology |
Elevation Oncology, Inc.
 Elevation Oncology, Inc. Pharmaceuticals: MajorHealth Technology Develops elevating precision medicines for cancer treatment | Health Technology |
Alpha-9 Oncology, Inc.
Alpha-9 Oncology, Inc. BiotechnologyHealth Technology Engages in research clinical stage radiopharmaceutical and drug design for cancer treatment | Health Technology |
